Nitrosamine: The Carcinogenic Impurity in Angiotensin Receptor Blockers

Authors

  • Sandip P. Zine
  • Sayli A. Sawant
  • Nilesh Mhapankar

Abstract

Angiotensin II Receptor Blockers (ARBs), commonly known as the Sartans, are used in the treatment of hypertension for a long time. Currently, seven Sartan drugs, i.e. Valsartan, Losartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, and Eprosartan, are in use. Recently, Nitroso impurity was detected in Valsartan active pharmaceutical ingredient, which led to the recall of batches of products containing it. Even in trace amounts, the impurity is said to be a probable human carcinogen. The impurity is thought to be formed by a change in the manufacturing process of Valsartan, which includes the use of Sodium azide. Also, impurities were detected in Losartan and Irbesartan as well. Regulatory bodies, such as the US FDA, have put forward some testing methods for detecting impurities. The impurities seen during the manufacturing process must be tested thoroughly and also care should be taken while making changes to the manufacturing process. This review focuses on the cause of impurity generation and also ways to avoid it

 

Keywords: Sartan drugs, Nitroso impurity, Human Carcinogen, US FDA, Sodium azide

 

Cite this Article

Sandip P. Zine, Miss. Sayli A. Sawant, Mr. Nilesh Mhapankar. Nitrosamine: The Carcinogenic Impurity in Angiotensin Receptor Blockers. Research & Reviews: Journal of Oncology and Hematology. 2020; 9(3): 36–43p.

Downloads

Published

2021-01-13

Issue

Vol. 9 No. 3 (2020)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.